{"filings":[{"id":1140484,"accession_number":"0001213900-26-070193","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2026-06-18T21:00:24+00:00","items":["8.01"],"status":"ready","headline":"Actinium submits NYSE American compliance plan after equity deficiency notice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received NYSE American deficiency notice on May 27, 2026, for Section 1003(a)(ii): equity below required $4M.","Submitted compliance plan on June 18, 2026, outlining intended actions to restore listing standards.","No specific plan details disclosed; exchange will review plan during continued trading.","Company faces potential delisting if plan not accepted or compliance not achieved within extension period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":748877,"accession_number":"0001213900-26-062935","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2026-05-29T21:10:41+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity $2.3M as of March 31, 2026, below NYSE American's $4M minimum; net losses in last 5 fiscal years.","Must submit compliance plan by June 26, 2026; deadline to regain compliance by November 27, 2027.","Company announced three ATNM-400 presentations at SNMMI 2026 (May 31-June 2) showing preclinical data in prostate cancer and NSCLC.","If plan not accepted or compliance not regained, delisting proceedings will commence; no immediate effect on trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103482,"accession_number":"0001213900-26-034807","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K/A","filed_at":"2026-03-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Actinium board adopts annual Say-on-Pay vote following shareholder advisory vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders at Nov 26, 2025 annual meeting preferred an annual Say-on-Pay frequency.","Board of directors on March 20, 2026 determined future Say-on-Pay votes will be held every year.","Next shareholder advisory vote on Say-on-Pay frequency will occur at the 2031 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103483,"accession_number":"0001213900-26-016559","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Actinium CFO Steve O'Loughlin resigns; CEO Sandesh Seth named principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steve O'Loughlin resigns as CFO effective Feb 27, 2026 to pursue other opportunities.","No disagreements with the company contributed to his resignation.","Board appoints CEO/Chairman Sandesh Seth as principal financial officer effective same date.","Sandesh Seth has 25+ years in pharma, investment banking, and equity research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119734,"accession_number":"0001213900-25-115586","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Actinium re-elects Shetty and Almenoff as Class III directors at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shetty elected with 5,032,369 for, 1,234,852 withheld; Almenoff with 5,284,503 for, 982,719 withheld.","Ratification of CBIZ as auditor: 13,724,478 for, 1,537,998 against, 232,097 abstain.","Non-binding advisory vote on executive compensation approved: 4,481,875 for, 1,541,460 against.","Advisory vote on frequency of say-on-pay: 1-year interval received most votes (4,645,270).","Total shares present: 15,494,573 of 31,195,891 outstanding; all proposals approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153427,"accession_number":"0001213900-25-041582","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Actinium dismisses Marcum, engages CBIZ CPAs as auditor after Marcum acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP dismissed as independent auditor on May 8, 2025, due to CBIZ CPAs acquiring its attest business.","CBIZ CPAs engaged as new auditor for fiscal year ending Dec 31, 2025, effective May 8, 2025.","No disagreements or reportable events occurred with Marcum during fiscal years 2024, 2023, and through May 8, 2025.","Marcum's audit reports for 2024 and 2023 were unqualified; Marcum provided a letter agreeing with the company's disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189153,"accession_number":"0001213900-24-103498","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Actinium re-elects Class II directors Seth and Chell, ratifies Marcum as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sandesh Seth and Jeffrey W. Chell re-elected as Class II directors for three-year terms expiring at 2027 annual meeting.","Marcum LLP ratified as independent registered public accounting firm for fiscal year ending Dec 31, 2024.","Approximately 63.2% of outstanding shares (19.7M of 31.2M) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189152,"accession_number":"0001213900-24-094622","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Actinium appoints June Almenoff, M.D., Ph.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Almenoff brings over 25 years of biopharma leadership; previously President and CMO of Furiex (acquired by Actavis/AbbVie for $1.2B).","She will serve on the Nominating and Corporate Governance Committee; term as Class III director expires at 2025 annual meeting.","Granted options for 50,000 shares at $1.71, vesting 28% at 12 months then 2% monthly thereafter.","Appointment effective November 1, 2024; experienced in translational medicine, clinical development, and regulatory submissions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205636,"accession_number":"0001213900-24-064993","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA requires additional Phase 3 trial for Iomab-B; SIERRA alone not adequate for BLA filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SIERRA met primary endpoint (dCR) with p<0.0001, but FDA now demands overall survival benefit in randomized head-to-head trial.","New trial required: Iomab-B plus Flu/TBI vs cyclophosphamide plus Flu/TBI; no crossover allowed (vs 60% crossover in SIERRA).","FDA suggests patient population could include all adult AML; specifics to be discussed in requested meeting.","Actinium will seek a strategic partner for Iomab-B in U.S. after FDA interactions; focus shifts to Actimab-A, Iomab-ACT, preclinical.","Management disappointed but will work with FDA; SIERRA supportive evidence for future BLA filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259494,"accession_number":"0001213900-23-092089","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2023-12-01T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Actinium shareholders re-elect Nicholson, Steinhart as Class I directors; Marcum LLP ratified as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Nicholson re-elected: 3,959,659 for, 3,275,844 withheld, 9,087,835 broker non-votes.","Richard Steinhart re-elected: 5,630,379 for, 1,777,251 withheld, 9,087,835 broker non-votes.","Marcum LLP ratified as independent auditor for FY2023: 15,842,146 for, 372,774 against, 280,545 abstain.","No other matters voted on at the November 30, 2023 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315170,"accession_number":"0001213900-23-019289","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Actinium confirms no deposits or accounts at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company holds no deposits, securities, or accounts at SVB.","FD disclosure made Mar 10, 2023, addressing SVB collapse exposure.","No financial impact or counterparty risk from SVB failure for Actinium."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315169,"accession_number":"0001213900-23-013059","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Actinium announces positive Phase 3 SIERRA trial results for Iomab-B in r/r AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Iomab-B met primary endpoint: 22% durable CR vs 0% control (p<0.0001).","Event-free survival HR=0.22 (78% risk reduction, p<0.0001).","Iomab-B doubled 1-year OS (26.1% vs 13.1%) and median OS (6.4 vs 3.2 months).","Sepsis rate 4x lower (6.1% vs 28.6%); 100% engraftment in Iomab-B arm.","Patients achieving dCR had 92% 1-year and 60% 2-year survival."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333509,"accession_number":"0001213900-22-084094","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2022-12-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Actinium shareholders approve 3.5M share increase for 2019 Plan; Shetty re-elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved an amendment to the 2019 Stock Plan increasing authorized shares by 3.5M to a total of 9,333,333 shares.","The proposal passed with 8,780,109 votes for, 8,533,767 against, and 103,453 abstentions, a narrow margin.","Ajit S. Shetty was elected as Class III director for a three-year term with 9,814,712 votes for and 2,964,185 against.","Shareholders ratified Marcum LLP as independent auditor for FY2022 with 16,368,122 votes for.","Non-binding advisory vote on executive compensation passed with 9,832,125 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333508,"accession_number":"0001213900-22-078586","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Actinium adjourns 2022 annual meeting to Dec 30 for more stockholder voting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Meeting originally scheduled Dec 8, 2022 adjourned to allow more time for voting.","Reconvened meeting set for Dec 30, 2022 at 9:30 a.m. ET in Garden City, NY.","Proxies previously submitted will be voted at reconvened meeting unless revoked.","Stockholders who haven't voted can vote via internet, phone, or mail by Dec 29.","Alliance Advisors assisting with proxy solicitation; stockholders can call for help."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333507,"accession_number":"0001213900-22-067378","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Actinium's Iomab-B meets primary endpoint in Phase 3 SIERRA AML trial (p<0.0001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 SIERRA trial of Iomab-B in AML patients 55+ with active relapsed/refractory disease met primary endpoint of durable complete remission (dCR) at 6 months with p<0.0001.","Iomab-B is a targeted radiotherapy conditioning regimen prior to bone marrow transplant; compared to conventional care with intent to transplant.","Company to submit Biologics License Application (BLA) to FDA for approval of Iomab-B; additional SIERRA data expected by year-end 2022.","CEO Sandesh Seth calls it a significant milestone; CMO Avinash Desai highlights statistical significance and increased access to BMT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368224,"accession_number":"0001213900-22-035693","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2022-06-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Actinium amends at-the-market sales agreement, adds B. Riley Securities as agent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Original Capital on Demand Sales Agreement (Aug 2020) allowed up to $200M in ATM offerings via JonesTrading.","A&R Sales Agreement dated June 28, 2022 adds B. Riley Securities as an additional sales agent.","No other material changes to terms; remaining $200M capacity unaffected.","Agreement filed as Exhibit 1.1; representations are for parties only, not factual disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368223,"accession_number":"0001213900-22-019512","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2022-04-13T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Actinium licenses Iomab-B to Immedica for $35M upfront plus up to $417M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $35 million from Immedica upon signing.","Eligible for aggregate regulatory/commercial milestones up to ~$417 million.","Royalties in mid-20% range on net sales in certain countries in licensed territory.","Immedica gets exclusive rights in EUMENA; Actinium retains U.S. and rest-of-world rights.","Actinium continues to handle clinical development and manufacturing of Iomab-B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":405508,"accession_number":"0001213900-21-057769","cik":1388320,"company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","form_type":"8-K","filed_at":"2021-11-09T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Actinium shareholders re-elect two Class II directors; approve 2.75M share increase to 2019 Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sandesh Seth and Jeffrey W. Chell re-elected as Class II directors for term expiring at 2024 annual meeting.","Shareholders approved Second Amendment to 2019 Plan, increasing available shares by 2,750,000 to total 5,833,333.","Marcum LLP ratified as independent auditor for FY 2021 with 12,371,473 votes for.","Broker non-votes totaled 6,568,275 on director elections and plan amendment.","Annual meeting had 12,755,273 shares present; no other matters were voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":35924362.38559322,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}